14th International workshop on multiple endocrine neoplasia and other rare endocrine tumors

Appendices

Author index

A

Akker, S.: SP8.4

Akslen, L.: FP5.3, P03, P11, P30

Alagaratnam, S.: FP2.1

Albers, M.: FP3.1

Albrecher, N.: P33

Alcázar, V.: P49

Alevizaki, M.: CP4.1

Allard, N.: P33

Allolio, B.: P24

Alves Serra, F.: P47

Amate, E.: P40, SP8.2

Amengual Galbarte, Á.: FP5.1

Ando, T.: FP5.2

Antoni, G.: P12

Antonodimitrakis, P.: FP7.1

Ares, J.: FP9.2, P49

Åsberg, A.: FP5.3, P30

Astudillo, A.: FP9.2

Augustyn, A.: P37

Ausems, M. G. E. M.: P50

B

Baciu, I.: P01, P31

Badiu, C.: P01

Baena, R. C.: P22

Balsalobre, M.: P40, P41

Bartsch, D. K.: FP3.1

Bartsch, O.: FP9.1

Bergant, D. M.: FP5.4, P32

Beristain, E.: FP9.2

Berney, D.: SP8.4

Bhattacharya, S.: P02

Bibb, J. A.: P36, P37, P38

Bickmann, J. K.: FP9.1

Bittenbring, J. T.: P25

Bjøro, T.: FP5.3, P30

Bohle, R.: P25

Bongers, P. J.: P35

Borel Rinkes, I. H. M.: P35

Bortolotto, L. A.: P22

Brain, C.: P19

Brandi, M.: CP4.2, P04, SP8.5

Brauckhoff, K.: P11, P30

Brauckhoff, M.: FP5.3, P03, P11, P30

Brazzarola, P.: P06

Brown, M.: P09

Bruegmann, P.: SP8.5

Brüggemann, O.: P43

Burgess, J.: P10

Butturini, G.: SP8.3

C

Cabral, J.: P47

Camera, L.: P39

Capatina, C.: P01

Carter, A.: P36

Casterás, A.: P49

Castro Fonseca, R.: P47

Castro, C. C.: P22

Castroneves, L. A.: FP7.2

Catteau, C.: SP8.5

Cavalli, T.: CP4.2, P04

Cayo, A. K.: P05

Chen, H.: P36

Chen, H.: P37

Chiara, M.-D.: FP9.2

Chorão, M.: P47

Christiansen, P.: P27

Cingarlini, S.: SP8.3

Cioppi, F.: P04

Clemente, C.: P44

Cochran, C.: FP3.2

Coculescu, M.: P01

Colao, A.: P39

Cole, D. E. C.: P14, P44

Conemans, E.: P10

Conemans, E. B.: P35

Cornelissen, C.: P10

Cote, G.: P05

Cote, G. J.: P37

Cotelli, F.: P13

Cottle-Delisle, C.: FP3.2

Crespo Hernández, I.: FP5.1, P07

Cuesta Hernández, M.: FP5.1, P07

D

Dahia, P. L. M.: P22

Dattani, M.: FP2.1, P19

Daviʼ, M. V.: P06, SP8.3

Davidson, J. M.: P14

de Castro Jr, G.: FP7.2

De Herder, W.: P10

de Jong, J.: SP8.5

de Laat, J. M.: P34, P35

De Luca, L.: P39

De Marinis, L.: CP4.1

De Martino, D.: P44

de Miguel Novoa, P.: FP5.1, P07

Del Prete, M.: P39

Di Candia, L.: P44

Díaz Pérez, J. Á.: FP5.1, P07

Dicitore, A.: P08, P13

Doknic, M.: P28

Drake, W.: FP1.1, P02, SP8.4

Dreijerink, K.: P09, P10

Drewitz, K. P.: SP8.5

Druce, M.: P02, SP8.4

DutchMEN1 Study Group (DMSG),: P34

E

Engebretsen, L.: FP5.3, P03, P11, P30

Eriksson, B.: FP7.1, P12

Eriksson, O.: P12

Ermon, V.: P06

Eva, S.: P30

Evans, D. B.: P05, P52

Ezzat Abdel-Aziz, T.: FP2.1, FP7.3, P19

F

Faggiano, A.: P39

Fagman, H.: P29

Fassnacht, M.: P24

Febrero, B.: P40, P41, SP8.2

Fendrich, V.: FP3.1, P51

Fernández Capel, F.: FP5.1, P07

Ferraù, F.: FP1.1

Fliers, E.: P10

Forga, L.: P49

Fottner, C.: CP4.5, FP9.1

Foulkes, W.: CP4.1

Francia, G.: P06, SP8.3

Freitas, R.: FP7.2

Frilling, A.: P20

Fuchs, R.: P18, SP8.1

Fujii, K.: FP5.2

G

Gabrovska, P.: CP4.1

Galoiu, S.: P01

Galzerano, A.: P47

Gaudenzi, G.: P08, P13

Genze, F.: P17

Ghaffari Tabrizi-Wizsy, N.: P33, SP8.1, P17, P18

Ghayee, H.: P36

Giudici, F.: CP4.2, P04

Giusti, F.: P04

Glavac, D.: FP5.4, P32

Glumac, N.: FP5.4, P32

Gómez Hoyos, E.: FP5.1, P07

Goudet, P.: SP8.5

Graham, P. H.: P05

Graziano, P.: P44

Grey, J. M.: SP8.5

Grøholt, K.: FP5.3, P30

Groner, A.: P09

Grubbs, E. G.: P05

Guarnieri, V.: P14, P44

H

Haas, H.: P33, SP8.1

Hassoun, R.: FP9.1

Havekes, B.: P10

Havre, R.: P03

Hayashi, H.: P46

Held, G.: P24

Helseth, K.: P30

Hendy, G. N.: P14, P44

Hernández Ramírez, L. C.: FP1.1

Herscovitch, P.: FP3.2

Hillmann, A.: P37

Hniyu, K.: P15

Hocevar, M.: FP5.4, P32

Hoeger, H.: SP8.1

Hoem, D.: P03

Hoff, A. O.: FP7.2

Hölzl, M.: P18

Horiuchi, K.: FP6.2, P15

Horvath, K.: P23

Horwath, C.: P33

Husebye, E.: P03, P11

I

Iacovazzo, D.: CP4.1

Imai, T.: FP5.2, P46

International FIPA Consortium,: P28

J

Johansson, E.: P29

Johansson, L.: P12

Johnsrud, C.: P30

Jørgensen, L.: FP5.3, P30

K

Kandeel, F.: P12

Kangasniemi, K. H.: P38

Karavitaki, N.: FP1.1

Kastelan, D.: FP1.1

Katai, M.: FP6.2

Kebebew, E.: FP3.2

Keck, F.: P20

Kelly, C.: P14

Khan, R.: SP8.4

Kikumori, T.: FP5.2, P16, P46

Kim, I.: P26

Kist, J. W.: P35

Kleinegger, F.: P17, P18

Knoop, R.: FP3.1

Koperek, O.: P45

Korbonits, M.: CP4.1, FP1.1

Korsgren, O.: P12

Kosaka, J.: FP5.2

Krump, C.: P18

Kubuschok, B.: P25

Kump, P.: P23

Kurzawinski, T.: FP2.1, FP7.3, P19

Kuznetsov, S.: P26

L

Lackner, L. J.: FP9.1

Lang, H.: CP4.5

Lee, J. E.: P05

Lewis, M.: CP4.3

Liang, S.: P29

Liedke, M.-O.: P20

Lipp, R. W.: P23

Lodewijk, L.: P35

Logoluso, F.: P44

Long, H.: P09

Lopez, C.: FP3.1

Louhibi, L.: P49

Lourenço Jr, D. M.: P21, P22

Lourenço, D. M.: CP4.4, FP7.2

Luca, P.: P13

Lucci-Cordisco, E.: CP4.1

Lucon, A. M.: P22

Lugli, F.: CP4.1

M

Machado Saraiva, A.: P47

Mader, J. K.: P23

Mæhle, L.: FP5.3, P30

Majidi, F.: P24, P25

Malpaga, A.: SP8.3

Mamedova, E.: P26

Mann, K.: SP8.4

Mannstadt, M.: P10

Marciello, F.: P39

Marotta, V.: P39

Marx, S. J.: FP3.2

Mathiesen, J. S.: P27

Melcher, R.: P24

Menéndez, E.: FP9.2

Mercado-Atri, M.: FP1.1

Merkel, R.: FP3.2

Merlo, A.: FP9.2

Mettlach, G.: P36

Midorikawa, S.: FP6.2

Miederer, M.: CP4.5

Miljic, D.: FP1.1, P28

Millo, C.: FP3.2

Minna, J. D.: P37

Modica, R.: P39

Mokrysheva, N.: P26

Moraes, M. B.: CP4.4

Morris, L. F.: P05

Morrison, P. J.: CP4.1

Mouri, Y.: FP5.2

Murawski, N.: P25

Muşat, M.: FP1.1

Musholt, T. J.: CP4.5, FP9.1

Musolino, N.: FP1.1

N

Nagai, E.: P15

Nakano, S.: FP5.2

Napolitano, V.: P39

Natori, K.: P15

Navarro, E.: P49

Newey, P.: SP8.5

Niederle, B.: P45, SP8.1

Nilsson, M.: P29

Nilubol, N.: FP3.2

Nwariaku, F.: P36, P37, P38

O

Okamoto, T.: FP6.2, P15

Opocher, G.: P06

Opsahl, E.: FP5.3, P30

Ortolá Buigues, A.: FP5.1, P07

P

Palumbo, O.: P14

Papadia, C. M.: FP7.2

Parrilla, P.: P40, P41, SP8.2

Passegger, C. A.: P17

Paun, D.: P31

Pekic, S.: P28

Penso Espinoza, R.: P07

Perhavec, A.: P32

Peric, B.: FP5.4, P32

Perrier, N. D.: P05

Persani, L.: P08

Pfragner, R.: P17, P18, P33, P43, SP8.1

Pieber, T. R.: P23

Pieterman, C.: P10, P34, P35

Plattner, F.: P36, P37, P38

Poiana, C.: P01, P31

Popovic, V.: P28

Portillo, P.: P40, P49, SP8.2

Poulsen, P. L.: P27

Pozo, K.: P36, P37, P38

Prete, F.: FP7.3, P19

R

Radian, S.: P01, P31

Ramundo, V.: P39

Rao, P.: P09

Recasens, M.: P49

Ribitsch, A.: P23

Rich, T. A.: P05

Riestra, M.: FP9.2

Ríos, A.: P40, P41, SP8.2

Riss, P.: P45

Rodrigues, K. C.: P21

Rodríguez, J. M.: P40, P41, SP8.2

Rohrer, K.: P33

Romanchishen, A.: P42

Romero Arenas, M. A.: P05

Romero, C.: P47

Ronchi, C.: P24

Ropero Luis, G.: FP5.1, P07

Roque, C.: P47

Rosmann, H.: FP9.1

Rozhinskaya, L.: P26

Ruiz Gracia, T.: FP5.1, P07

S

Sadjak, A.: P17, P33, SP8.1

Sadowski, S. M.: FP3.2

Sagiyama, K.: P38

Sakaguchi, T.: P15

Sakamoto, A.: P15

Sakurai, A.: FP6.2

Salcuni, A. S.: P44

Sampson, J. R.: CP4.1

Santana, L. S.: CP4.4

Saraiva, C.: P47

Sbiera, S.: P24

Schaad, A.: FP9.1

Schaaf, L.: SP8.5

Schad, A.: CP4.5

Scheuba, C.: P45

Schiavi, F.: P06

Schlöricke, E.: P20

Schoefberger, W.: P43

Schwach, G.: P17, P33, P43, SP8.1

Schwarzenberger, E.: P33

Schweighofer, B.: P17

Scillitani, A.: P14, P44

Seaberg, R. M.: P14

Segura, P.: P41, SP8.2

Sekiya, T.: CP4.4, P22

Selberherr, A.: P45

Selvaraju, R.: P12

Sequeira Duarte, J.: P47

Simões, H.: P47

Singh, T.: P36, P37

Siqueira, S. A. C.: P22

Sjursen, W.: P30

Skogseid, B.: FP7.1

Slater, E.: FP3.1

Sollfrank, S.: FP9.1

Sörensen, J.: P12

Spoudeas, M.: P19

Stochholm, K.: P27

Stojanovic, M.: P28

Suárez, C.: FP9.2

Sundin, A.: FP7.1

Svartberg, J.: P30

T

Takahashi, M.: P38

Takeuchi, D.: FP5.2, P46

Tam Amersdorfer, C.: P33, SP8.1

Tavares Bello, C.: P47

Tavares, M. R.: FP7.2

Teasdale, I.: P43

Tébar, J.: P40, P41, P49, SP8.2

Tetsuka, R.: FP5.2

Thakker, R. V.: SP8.5

Tiulpakov, A.: P26

Toaiari, M.: P06

Tobias, T.: P20

Tokumitsu, H.: P15

Toledo, R. A.: CP4.4, P21, P22

Toledo, S. P. A.: CP4.4, P21, P22

Tonelli, F.: CP4.2, P04, SP8.5

Torregrosa, N.: P40, SP8.2

Torres, G.: P41

Treiber, G.: P23

Triponez, F.: P48

Twisk, J. W. R.: P34

U

Uchino, S.: P16

V

Vabalayte, K.: P42

Valdés, N.: FP9.2, P49

Valk, G. D.: P34, P35, P50, SP8.5

Van Blokland, M.: P10

van den Broek, M. F.: P50

van Nesselrooij, B. P. M.: P50

van’t Hoff, W.: FP2.1

Varhaug, J.: FP5.3, P30

Velikyan, I.: P12

Vestergaard, E. M.: P27

Vestergaard, P.: P27

Vicente, Á.: FP9.2

Vitale, G.: P08, P13

von Feldmann, F.: P20

Vriens, M. R.: P34, P35

Vyas, S.: P02

W

Waldmann, J.: FP3.1, FP6.1, P24, P51

Wassberg, C.: FP7.1

Waterhouse, M.: SP8.4

Watzka, F. M.: CP4.5

Weber, M. M.: CP4.5, FP9.1

Wild, V.: P24

Wilfert, S.: P43

Williams, M. D.: P05

Wilson, S. D.: P52

Winceslaus, J.: SP8.4

Y

Yamazaki, M.: FP6.2

Yanagibori, R.: FP6.2

Yang, L.: FP3.2, SP8.4

Yoshida, M.: FP5.2

Yoshida, Y.: P15

Z

Zerbini, M. C. N.: P22

Zimmermann, M.: P20

Zwick, C.: P24, P25

Keyword index

111In-pentetreotide scan: FP3.2

5’UTR: P14

68 Ga: P12

68Gallium-DOTATATE: FP3.2

A

A883F: P27

Acromegaly: FP1.1, P48

adenoma: CP4.2, P28

Adrenal: P25

Adrenalectomy: FP7.3, P49

Adrenocortical carcinoma: CP4.3, P24

Advanced thyroid cancer: P42

AIP: FP1.1, P01

Animal models: P36

Anticipation: P50

Antineoplastic effects: P43

Anti-proliferative effects: P39

Anxiety: P21

ASS: FP6.1

Atypical presentation: P44

Autotransplantation: FP5.2

AUY922: P51

B

Breast Cancer Susceptibility: P10

Breast Cancer: P10

Bronchial: SP8.4

C

C cells: P29

C634 mutation: P49

C634R mutation: SP8.2

Calcitonin: FP5.1

CAM: P17

Cancer stem cells: P18

Carcinoid: SP8.4

C-cell hyperplasia: FP5.1

CDC73: P05, P14

Cdk5: P36, P37, P38

Cell lines: P43

Characteristic: P28

Chemoprevention: FP6.1

Chemotherapy: FP7.1, P25

CHES1: FP3.1

Chick chorioallantoic membrane: P17

Chick embryo: P17

Children: P19

Chromatin immunoprecipitation: P09

Chromatin modification: P09

Cinacalcet: CP4.2

Clinical presentation: P06

Clinical screening: P22

Clinical: SP8.4

Clinics: P32

Codon 790: P32

CYS634ARG mutation: SP8.2

Cystic parathyroid: CP4.2

Cytostatic effects: P33

D

Decreased proliferation: P33

Depression: P21

Diagnosis: P14, P23

Disease-free survival: P46

DNA microarray: P37

Duodenal Hormones: P52

Duodeno-pancreatic NETs: P39

Dutch cohort: P50

E

Early-stage NETs: P39

Embryo: P13

Enalapril: FP6.1

Epigenetic agent: P08

Epirubicin: P43

European collaboration: SP8.5

Exendin-4: P12

F

Familial paraganglioma syndromes: FP9.1

Familial pheochromocytoma syndromes: FP9.1

Familial: CP4.1, P28

Fibromyxosarcoma: CP4.4

FIPA: FP1.1

Focal neurological findings: P47

Follow up: FP5.2, SP8.3

Foregut: SP8.4

Forkhead: P29

Foxa1: P29

Foxa2: P29

Full gene sequencing: P11

G

Gastrinoma: P20

Gender difference: FP6.2

Gene expression: P08

Genetic examination: P11

Genetic mutation: FP2.1

Genetic screening: P06, P22

Genetic testing: FP9.2, P05, P30

Genetics: CP4.1, P01¸ P28

Germinal mutations: P06

Germline mutation: P27, P44

GLP-1R: P12

Grading: FP7.1

Growth rate: P34

gsp oncogene: FP1.1

Guidelines: SP8.5

H

H3K4 trimethylation: P09

Hepatic metastasis: CP4.5

Hereditary medullary thyroid cancer: FP5.1

Hereditary paraganglioma: P07

Hereditary pheochromocytoma: P07

Hereditary syndrome: P26

High level MSI: P24

HPT-JT: P14

HSP90: P51

Human tumors: P36

Hypercalcemia: FP2.1

Hyperparathyroidism: CP4.2, CP4.3, P11, P26

Hyperplasia: P16

I

Immunohistochemistry: FP9.2

In vitro models: SP8.1

Incidentalomas: P35

Individualized patient care: SP8.5

Insulinoma: P02, P12, P48

Intron: FP5.4

J

Jaw tumor syndrome: P05

K

K666N: P16

Kindred: P11

L

Lanreotide: P39

Laparoscopic: P20

Large deletion: P14

Lipoma: P44

Localisation: P02

LOH: CP4.4

Longevity: P52

Loss of heterozygosity: P10

Low Level MSI: P24

lung carcinoid: P48

Lymphoma: P25

M

M918T RET proto oncogene mutation: FP5.3

Malignancy: FP7.3, P04

Maxillary myxoma: CP4.4

Medullary carcinoma: P40

Medullary thyroid cancer: P13, P17

Medullary thyroid carcinoma: FP5.3, FP7.2, P08, P16, P27, P29, P30, P31, SP8.1

MEN 2A syndrome: SP8.2

MEN 2A: P30, P42

MEN 2b: P42

MEN I: CP4.5

MEN1 gene: CP4.4

MEN1: CP4.2, CP4.3, FP3.1, FP3.2, FP5.2, FP6.2, P03, P04, P11, P26, P34, P35, P41, P42, P44, P48, P50, P52, SP8.3, SP8.4

MEN1-Syndrome: P45

MEN2: FP5.2, P19

Menin: P09, P10

Meningitis Lymphomatosa: P25

MEN-I-Syndrome: P20

Metabotropic glutamate receptor-1 (mGluR1) antago: P33

Metastasis: P18

Metastatic: FP7.2

MIBG: FP7.3

Micrsatellite: P24

Morphological changes: P33

Mouse model: FP6.1, P37, P38, P51

MTC: CP4.1, FP5.4, P32, P37, P38

mTOR: P08

Multiple endocrine neoplasia 2B: P27

Multiple Endocrine Neoplasia type 1: CP4.4, P09, P10, P15, P35, P39

Multiple endocrine neoplasia type 2 A: P49

Multiple endocrine neoplasia type 2: FP5.1, P07, P21, P40

Multiple endocrine neoplasia: FP5.3, P30

Multiple pancreatic neuroendocrine neoplasms: P45

Mutation: CP4.1, P01, P31

N

Natural course: P34

NEC: CP4.5

Needle Biopsy: P25

Neonatal: FP2.1

Nesidioblastosis: P23

NET: FP6.2

Neuroendocrine cell line: P18, P33

Neuroendocrine tumor cell lines: SP8.1

Neuroendocrine tumor: FP3.2, P03, P41, P43

Neuroendocrine: CP4.5, P36

Neurofibromatosis type 1: P07

NF-PET: P48

Non functioning pancreatic NET: SP8.3

Non-functioning: P03

Normetanephrines: P47

O

Oral neuromas: FP5.3

Orphan disease: FP5.3

Overall survival: P46

P

Pancreas: FP6.1, P02, P03

Pancreatic NET: FP7.1

Pancreatic neuroendocrine tumor: P34

Pancreatic resection: FP3.1

Pancreatic tumors: P41

Pancreaticoduodenectomy: P20, P52

Papillary carcinoma: P40

Parafibromin: P05

Paraganglioma: FP7.3, FP9.1, FP9.2, P06, P46, P47

Parathyroid carcinoma: P44

Parathyroidectomy: FP2.1, FP5.2, P15

Parsireotide: P23

Patient empowerment: SP8.5

Pediatrics: CP4.3

Penetrance: P22, SP8.2

Personalized care: P50

Phaeochromocytoma: FP7.3

Pheochromocytoma: FP9.2, P22, P46, P49

Pheocromocytoma: P06

pituitary adenoma: P01

Pituitary tumor: FP6.2

Pituitary: P28

Pleuritic pain: P47

pNEN: FP3.1, P45, P51

pNET: P34, P52

Polymorphism: P26

Polyphosphazene: P43

Positron Emission Tomography: FP3.2, P12

Postoperative prognosis: P46

Potassium channel: P24

Preclinical: P38

Primary hyperparathyroidism: FP6.2, P05, P15, P16

Prognosis: SP8.3

Prognostic factors: P41

Progression: FP7.2

Prophylactic: P19

Psychological Well-Being: P21

PTH: P26

Pulmonary: P47

Q

Quality of Life: P21

R

Radical surgery: P04

Rb: P37

Resection: P02

RET mutation: P40, P49

RET proto oncogen mutation: P30

RET proto-oncogen: FP5.1, FP5.4 P27, P32, SP8.2

RET: CP4.1, P16, P31

Retrospective: FP5.4

Romanian: P31

S

Scintigraphy: P23

Screening: CP4.3, FP5.4, P01, P31, P32

SDH: FP9.1

SDHB: FP9.2

Severe: FP2.1

Signal transduction: P36

Small intestinal neuroendocrine tumors (SI-NETs): SP8.1

Somatotropinoma: FP1.1

Sorafenib: FP7.2

Splenic Preservation: P20

Sporadic neuroendocrine tumors: P41

Stomach: CP4.5

Streptozocin: FP7.1

Subtotal parathyroidectomy: P15

Supranational database: SP8.5

Surgery: FP3.1, P02

Surgical strategy: P45

Surgical treatment: P42

Surveillance: P03, P50

T

Targeted therapy: P08

Thyroid carcinoma: P40

Thyroid: P19, P35

Thyroidectomy: P19

TMEM127: P22

Total parathyroidectomy: P15

Toxicity: FP7.1

Treatment: P23, P38, SP8.3

Tumor angiogenesis: P13

Tumor growth: P51

Tumor progression: P45

Tumor xenograft: P13

Tumour growth: P18

Tumourigenesis: P18

Tyrosine kinase inhibitor: FP7.2

U

Üheochromocytoma: FP9.1

Ultrasound: P35

V

Ventricular fibrillation: P04

VIPoma: P04

Von-Hippel Lindau disease: P07

X

Xenograft model: P17

Xenotransplants: SP8.1

Zebrafish: P13